LATEST NEWS

Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of WAHO.

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

May 28, 2026

Chris Ryan

The FDA has approved durvalumab in combination with BCG for the treatment of adult patients with BCG-naive, high-risk NMIBC.

FDA Grants Priority Review to Bezuclastinib Plus Sunitinib for Previously Treated GIST

May 28, 2026

Courtney Flaherty

The FDA has accepted for review an NDA for bezuclastinib plus sunitinib in imatinib-pretreated GIST, with a PDUFA date of November 30, 2026.

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

May 28, 2026

Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center researchers will share key data at the 2026 ASCO Annual Meeting.

Rising Early-Onset Cancer Incidence Prompts Novel Management Strategies, Research

May 28, 2026

Chris Ryan

Rising rates of early-onset cancers have prompted shifts in management strategies and new research avenues.

Zanidatamab Plus Chemo ± Tislelizumab Improves Survival in HER2+ Gastroesophageal Adenocarcinoma

May 27, 2026

OncLive Staff

The zanidatamab triplet significantly improved both PFS and OS vs trastuzumab plus chemotherapy in HER2-positive gastroesophageal cancer.

FDA Approves Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm

May 27, 2026

Chris Ryan

The FDA has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm.

Experts Recap the Most Notable Data in GU Cancers Presented During the 2026 AUA Annual Meeting

May 27, 2026

Kyle Doherty

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

FDA Grants Priority Review to Neladalkib for TKI-Pretreated ALK+ NSCLC

May 27, 2026

Kyle Doherty

The FDA priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.

AI May Help Identify Survivors of Cancer at Risk for Emergency Visits, Worsening Symptoms

May 27, 2026

Sylvester Comprehensive Cancer Center

Researchers found machine learning models using patient-reported outcomes and clinical data could help forecast unplanned health care use after treatment.

FDA Extends Decision Date for Camizestrant in HR+ Advanced Breast Cancer With an Emergent ESR1 Mutation

May 27, 2026

Ashling Wahner

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.

Novel GPRC5D-Directed CAR T-Cell Therapy Produces Durable Remissions in R/R Myeloma

May 27, 2026

OncLive Staff

RD118 produced an ORR of 94.4% and a median PFS of 18.2 months in heavily pretreated patients with relapsed/refractory multiple myeloma.

DSMB Recommends Continuation of Bria-IMT Investigation in Metastatic Breast Cancer

May 26, 2026

Ashling Wahner

A DSMB has recommended the continuation of the BRIA-ABC trial evaluating Bria-IMT in patients with metastatic breast cancer, with no safety concerns.

Dana-Farber Researchers to Present Two Plenary Studies and Additional Late-Breaking Cancer Research at 2026 ASCO

May 26, 2026

Dana-Farber Cancer Institute

Studies in pancreatic and prostate cancer selected for ASCO’s Plenary Program.

Resectability Status Drives Treatment Decisions Amid Expanding Immunotherapy Use in CSCC

May 26, 2026

Courtney Flaherty

Neil D. Gross, MD, FACS, discusses how anti–PD-1 therapy is changing treatment approaches in advanced CSCC.

CHMP Backs Encorafenib Plus Cetuximab and FOLFOX as First-Line Option for BRAF V600E–Mutant mCRC

May 26, 2026

Courtney Flaherty

The European Medicines Agency’s CHMP has issued a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in first-line BRAF V600E–mutant mCRC.